PBF-680 is under clinical development by Palo BioFarma and currently in Phase II for Chronic Obstructive Pulmonary Disease (COPD). According to GlobalData, Phase II drugs for Chronic Obstructive Pulmonary Disease (COPD) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how PBF-680’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PBF-680 overview
PBF-680 is under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug candidate is formulated as capsule and administered orally. It acts by targeting adenosine A receptor (ADORA1). It is chemically a non-xanthine with non BBB (Blood Brain Barrier) permeability.
Palo BioFarma overview
Palo BioFarma is a Spanish biotechnology company. The scientists with experience in drug discovery in several pharmaceutical companies and mission of the Palobiofarma is to discover new drugs based on the modulation of adenosine receptors. The company is headquartered Mataró, Barcelona, Spain.
For a complete picture of PBF-680’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
